Downregulation of amine oxidase copper containing 1 inhibits tumor progression by suppressing IL‑6/JAK/STAT3 pathway activation in hepatocellular carcinoma

Ding,Qian; Lin,Dongdong; Zhou,Yajing; Li,Feng; Lai,Jianming; Duan,Jianping; Chen,Jing; Jiang,Caihua

doi:10.3892/ol.2021.13118

Downregulation of amine oxidase copper containing 1 inhibits tumor progression by suppressing IL‑6/JAK/STAT3 pathway activation in hepatocellular carcinoma

Authors:
- Qian Ding
- Dongdong Lin
- Yajing Zhou
- Feng Li
- Jianming Lai
- Jianping Duan
- Jing Chen
- Caihua Jiang
View Affiliations

Affiliations: Department of Infectious Disease, Qingdao No. 6 People's Hospital, Qingdao, Shandong 266033, P.R. China, Blood Purification Center, Qingdao No. 6 People's Hospital, Qingdao, Shandong 266033, P.R. China, Department of Physical Therapy, Qingdao No. 6 People's Hospital, Qingdao, Shandong 266033, P.R. China, School of Clinical Medicine, QingDao University Medical College, Qingdao, Shandong 266071, P.R. China, Department of Eight Areas of Liver Disease, Qingdao No. 6 People's Hospital, Qingdao, Shandong 266033, P.R. China, Outpatient Department, Qingdao No. 6 People's Hospital, Qingdao, Shandong 266033, P.R. China
Published online on: October 30, 2021 https://doi.org/10.3892/ol.2021.13118
Article Number: 857
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Amine oxidase copper containing 1 (AOC1) is a copper‑containing amine oxidase that catalyzes the deamination of polyamines. AOC1 functions as an oncogene in human gastric cancer. There is little information available regarding the function of AOC1 in hepatocellular carcinoma (HCC). In the present study, reverse transcription‑quantitative PCR was used to detect the expression levels of AOC1 in HCC tissues, and the role of AOC1 in HCC progression was determined using western blot, Cell Counting Kit 8, clone formation, wound‑healing and Transwell assays. An AOC1 survival curve was generated with data downloaded from The Cancer Genome Atlas, and Gene Set Enrichment Analysis was performed to investigate the potential biological mechanisms of AOC1 in HCC. AOC1 was found to be upregulated in HCC tissues, which was associated with a poor prognosis. Furthermore, AOC1‑knockdown inhibited HCC cell proliferation, migration and invasiveness, suppressed IL‑6 expression, as well as decreasing JAK2 and STAT3 phosphorylation. Ultimately, the results of the present study illustrate that AOC1 promoted the proliferation, migration and invasiveness of HCC cells by regulating the IL‑6/JAK/STAT3 pathway.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM and Shoreibah MG: Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol. 25:1550–1559. 2019. View Article : Google Scholar : PubMed/NCBI
3	Petruzziello A: Epidemiology of hepatitis B virus (HBV) and hepatitis C Virus (HCV) related hepatocellular carcinoma. Open Virol J. 12:26–32. 2018. View Article : Google Scholar : PubMed/NCBI
4	Liu CY, Chen KF and Chen PJ: Treatment of liver cancer. Cold Spring Harb Perspect Med. 5:a0215352015. View Article : Google Scholar : PubMed/NCBI
5	Wang EA, Stein JP, Bellavia RJ and Broadwell SR: Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Int J Clin Pract. 71:302017. View Article : Google Scholar : PubMed/NCBI
6	Hartke J, Johnson M and Ghabril M: The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 34:153–159. 2017. View Article : Google Scholar : PubMed/NCBI
7	Toninello A, Pietrangeli P, De Marchi U, Salvi M and Mondovì B: Amine oxidases in apoptosis and cancer. Biochim Biophys Acta. 1:1–13. 2006.PubMed/NCBI
8	Schwelberger HG: Structural organization of mammalian copper-containing amine oxidase genes. Inflamm Res. 59 (Suppl 2):S223–S235. 2010. View Article : Google Scholar : PubMed/NCBI
9	Sun WY, Choi J, Cha YJ and Koo JS: Evaluation of the expression of amine oxidase proteins in breast cancer. Int J Mol Sci. 18:27752017. View Article : Google Scholar : PubMed/NCBI
10	Vakal S, Jalkanen S, Dahlström KM and Salminen TA: Human copper-containing amine oxidases in drug design and development. Molecules. 25:12932020. View Article : Google Scholar : PubMed/NCBI
11	Xu F, Xu Y, Xiong JH, Zhang JH, Wu J, Luo J and Xiong JP: AOC1 contributes to tumor progression by promoting the AKT and EMT pathways in gastric cancer. Cancer Manag Res. 12:1789–1798. 2020. View Article : Google Scholar : PubMed/NCBI
12	Nourbakhsh M, Farzaneh S, Taghikhani A, Zarghi A and Noori S: The effect of a newly synthesized ferrocene derivative against MCF-7 breast cancer cells and spheroid stem cells through ROS production and inhibition of JAK2/STAT3 signaling pathway. Anticancer Agents Med Chem. 20:875–886. 2020. View Article : Google Scholar : PubMed/NCBI
13	Cao Y, Wang J, Tian H and Fu GH: Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer. J Exp Clin Cancer Res. 39:1192020. View Article : Google Scholar : PubMed/NCBI
14	Li J, Pu T, Yin L, Li Q, Liao CP and Wu BJ: MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness. Oncogene. 39:3305–3321. 2020. View Article : Google Scholar : PubMed/NCBI
15	Lee HM, Sia APE, Li L, Sathasivam HP, Chan MSA, Rajadurai P, Tsang CM, Tsao SW, Murray PG, Tao Q, et al: Monoamine oxidase A is down-regulated in EBV-associated nasopharyngeal carcinoma. Sci Rep. 10:61152020. View Article : Google Scholar : PubMed/NCBI
16	Therneau TM: Survival Analysis [R package survival version 2.41–3]. Technometrics. 46:111–112. 2015.
17	Li ZS and Li Q: The latest 2010 WHO classification of tumors of digestive system. Zhonghua Bing Li Xue Za Zhi. 40:351–354. 2011.(In Chinese). PubMed/NCBI
18	Hoshi T, Watanabe Miyano S, Watanabe H, Sonobe RMK, Seki Y, Ohta E, Nomoto K, Matsui J and Funahashi Y: Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. Biochem Biophys Res Commun. 513:1–7. 2019. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Jiang H, Zhou Z, Jin S, Xu K, Zhang H and Xu J, Sun Q, Wang J and Xu J: PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3β/Snail signaling. Cancer Sci. 109:1414–1427. 2018. View Article : Google Scholar : PubMed/NCBI
21	Giannelli G, Koudelkova P, Dituri F and Mikulits W: Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
22	Ivanova ON, Snezhkina AV, Krasnov GS, Valuev-Elliston VT, Khomich OA, Khomutov AR and Keinanen TA: Activation of Polyamine Catabolism by N¹,N11-Diethylnorspermine in Hepatic HepaRG cells induces dedifferentiation and mesenchymal-like phenotype. Cells. 7:2752018. View Article : Google Scholar : PubMed/NCBI
23	Wen B, Xu LY and Li EM: LOXL2 in cancer: Regulation, downstream effectors and novel roles. Biochim Biophys Acta Rev Cancer. 1874:1884352020. View Article : Google Scholar : PubMed/NCBI
24	Moon HJ, Finney J, Xu L, Moore D, Welch DR and Mure M: MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. J Biol Chem. 288:30000–30008. 2013. View Article : Google Scholar : PubMed/NCBI
25	Moloney JN and Cotter TG: ROS signalling in the biology of cancer. Semin Cell Dev Biol. 80:50–64. 2018. View Article : Google Scholar : PubMed/NCBI
26	Dong Y, Wu Z, He M, Chen Y, Chen Y, Shen X, Zhao X, Zhang L, Yuan B and Zeng Z: ADAM9 mediates the interleukin-6-induced Epithelial-Mesenchymal transition and metastasis through ROS production in hepatoma cells. Cancer Lett. 421:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
27	Binker MG, Binker-Cosen AA, Gaisano HY, de Cosen RH and Cosen-Binker LI: TGF-β1 increases invasiveness of SW1990 cells through Rac1/ROS/NF-κB/IL-6/MMP-2. Biochem Biophys Res Commun. 405:140–145. 2011. View Article : Google Scholar : PubMed/NCBI
28	Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, Stanger BZ, Chung I, Rhim AD and di Magliano MP: Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 73:6359–6374. 2013. View Article : Google Scholar : PubMed/NCBI
29	Browning L, Patel MR, Horvath EB, Tawara K and Jorcyk CL: IL-6 and ovarian cancer: Inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 10:6685–6693. 2018. View Article : Google Scholar : PubMed/NCBI
30	Bromberg J and Wang TC: Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell. 15:79–80. 2009. View Article : Google Scholar : PubMed/NCBI
31	Gao Y, Li W, Liu R, Guo Q, Li J, Bao Y, Zheng H, Jiang S and Hua B: Norcantharidin inhibits IL-6-induced epithelial-mesenchymal transition via the JAK2/STAT3/TWIST signaling pathway in hepatocellular carcinoma cells. Oncol Rep. 38:1224–1232. 2017. View Article : Google Scholar : PubMed/NCBI
32	Chen J, Wang S, Su J, Chu G, You H, Chen Z, Sun H, Chen B and Zhou M: Interleukin-32α inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer cells. Onco Targets Ther. 9:4225–4237. 2016. View Article : Google Scholar : PubMed/NCBI